Statement: 100% of patients in the primary trial suffered adverse events.
Primary_evidence: Outcome Measurement:    Safety and Tolerability in Terms of Number of Patients With Adverse Events (Serious and Non-serious)   [Not Specified]   Time frame: 3 years, 10 months (Adverse events recorded from patient screening to discontinuation plus 28 days safety follow-up). Results 1:    Arm/Group Title: AZD4547 80mg bd Cont + Ex 25mg   Arm/Group Description: 80 mg AZD4547 BD continuous + 25 mg exemestane   Overall Number of Participants Analyzed: 5   Measure Type: Number   Unit of Measure: Participants  5 Results 2:    Arm/Group Title: AZD4547 40mg Cont + Ex 25mg   Arm/Group Description: 40 mg AZD4547 BD continuous + 25 mg exemestane   Overall Number of Participants Analyzed: 5   Measure Type: Number   Unit of Measure: Participants  5